Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2008
07/30/2008CN100406005C Compound and method for therapeutic intervention in preventing diabetic complications
07/30/2008CA2619799A1 Methods for evaluating and implementing prostate disease treatments
07/29/2008US7405323 Invention provides five novel polymorphic forms of modafinil racemate called CRL 40476 form III, CRL 40476 form IV, CRL 40476 form V, CRL 40476 form VI, CRL 40476 form VII; preparing a new solvate of modafinil comprising dissolving in solvent and crystallizing; sleep disorders
07/29/2008US7405311 N-(trans-2,3-di-n-amyl-2-butenoic acid amide)-L-phenylglycinamide;treating hypertension, deficiency of magnesium ion bound to the plasma membranes of their somatic cells; sodium-sensitive essential hypertension and Type 2 insulin-resistant diabetes mellitus
07/29/2008US7405310 Non-nucleoside reverse transcriptase inhibitors
07/29/2008US7405309 e.g. iodomethylene-dimethyl-dihydropyranone; novelty of the chemical structure and of the mechanism of action; alkylation aldehyde with methyl [bis(2,2,2-trifluoroethyl)phosphinoyl]acetate followed by cyclization
07/29/2008US7405307 N-(p-(2-alpha-carboxybenzylamino)ethylamino)phenyl)p-(p-trifluoromethylphenyl)benzamide; antiobesity and anti-type II diabetic agents
07/29/2008US7405306 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease
07/29/2008US7405305 Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
07/29/2008US7405303 e.g. 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid; bone diseases, aging, osteoporosis, osteoarthritis, atherosclerosis, menopausal disorders,liver and cardiovascular disorder, breast cancer
07/29/2008US7405300 Central nervous system disorders; cardiovascular disorders; antiischemic agents; strokes; antiarthritic agents; anticancer agents; muscular disorders
07/29/2008US7405297 3-amino-2-ethoxycarbonylpyrrole; chemical intermediate in synthesis of 3H,5H-pyrrolo[3,2-d]pyrimidin-4-one; a convergent synthesis route rather than a linear one
07/29/2008US7405295 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
07/29/2008US7405240 Use treating glaucoma, ocular hypertension, or baldness; prostaglandin EP2 selective agonists are 1-hydroxy-3-chloro-4-carboxylalk(en)yl-5-(aryloxyalkyl)cyclopentanes
07/29/2008US7405239 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction
07/29/2008US7405238 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
07/29/2008US7405237 Isoindoline compounds and methods of their use
07/29/2008US7405236 e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis
07/29/2008US7405235 Benzimidazoles for antibiotic resistance of cells
07/29/2008US7405234 Bicyclic modulators of androgen receptor function
07/29/2008US7405233 e.g. 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]-BENZOIC ACID SODIUM SALT; method of modulating premature translation termination and/or nonsense-mediated mRNA decay in a cell in vitro; cystic fibrosis or Duchenne muscular dystrophy
07/29/2008US7405232 Long acting beta-2 agonists and their use as medicaments
07/29/2008US7405231 Oxidized thioether derivatives
07/29/2008US7405230 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
07/29/2008US7405229 N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders
07/29/2008US7405228 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites
07/29/2008US7405226 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
07/29/2008US7405225 Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
07/29/2008US7405224 Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
07/29/2008US7405223 Treating allergic and inflammatory conditions
07/29/2008US7405222 Administering a drug, e.g., a vasodilator, by intracavernosal pharmacotherapy after assessing the general, physical and psychological condition of the male, determining a test dosage and adjusting the dosage to provide suitable results
07/29/2008US7405221 2-(4-fluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine; antagonists or inverse agonists of the Cannabinoid-1 (CB1) receptor; antidepressant, neuroleptic, anxiolytic, antiinflammatory agent, cognition activator; psychosis, epilepsy, Parkinson's disease, and schizophrenia
07/29/2008US7405220 Pyrazolopyrimidines
07/29/2008US7405219 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine; adenosine receptor antagonist; antidepressant, neurodegenerative disorders, cognition activator, attention deficit disorder
07/29/2008US7405218 Isothiazole derivatives useful as anticancer agents
07/29/2008US7405217 N-aroyl piperazine derivatives as orexin receptor antagonists
07/29/2008US7405216 Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
07/29/2008US7405215 e.g. [3-(3-benzyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-indol-1-yl]-acetic acid; inhibit binding of endogenous ligands, including prostaglandin PGD2 and its metabolites and certain thromboxane metabolites (such as 11-dehydro-TXB2), to CRTH2; antiallergent; asthma, bronchitis, rhinitis, cough, psoriasis
07/29/2008US7405214 Antitumor agents; 2-fluoro-cyclopentenyl nucleosides such as 4-Amino-1-(2-fluoro-4-hydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one; synthesis using 1-((4S,5S)-2,2-Dimethyl-5-vinyl-1,3-dioxolan-4-yl)-2-trityloxy-ethanone intermediates
07/29/2008US7405213 such as 3-chloro-4-fluoro-N-(5-{[6-({3-[4-(hydroxymethyl)piperidin-1-yl]propyl}oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyrimidin-2-yl)benzamide; serine/threonine Aurora kinase inhibitor; anticarcinogenic agent
07/29/2008US7405211 Therapeutic morpholino-substituted compounds
07/29/2008US7405210 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
07/29/2008US7405209 Protease inhibitors
07/29/2008US7405208 Benzoquinone ansamycins
07/29/2008US7405207 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
07/29/2008US7405206 Administering by inhalation; antiinflammatory agents, antiallergens; skin disorders; reacting androstane compound with 2-oxofuran compound
07/29/2008US7405204 Nucleoside compounds for treating viral infections
07/29/2008US7405200 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
07/29/2008US7405194 Therapeutic agents and methods of use thereof for the treatment of melanoma
07/29/2008US7405080 Compositions and methods relating to prevention of chemotherapy-induced alopecia
07/29/2008US7404970 Pain relief composition, method to form same, and method to use same
07/29/2008US7404968 unit aliquot dose of a pharmaceutical electricstatically deposited on a porous, permeable or semi-permeable ingestible membrane; including two or more active pharmaceuticals segregated from one another in a single delivery package.
07/29/2008US7404967 A water-soluble divalent strontium cation in a suitable topical formulation vehicle; preferably, strontium nitrate, strontium chloride and strontium acetate; cosmetics; drugs soaps; detergents; antiallergens
07/29/2008US7404964 Complex of antibiotic and fatty acid; sustained release; extended release time, maximum stability and efficacy, reduced toxicity, maximum reproducibility in preparation, and the elimination of unwanted physical, biochemical, or toxicological effects introduced by undesirable matrix materials
07/29/2008US7404962 Combination kit used in the treatment of malaria
07/29/2008US7404954 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms
07/29/2008US7404951 Intravenously administering glutamate modifying enzyme and co-factor to enhance brain to blood efflux; transaminase, dehydrogenase, decarboxylase, ligase
07/29/2008CA2515596C Cannabinoid receptor ligands and uses thereof
07/29/2008CA2460939C Substituted pyrazolyl compounds for the treatment of inflammation
07/29/2008CA2438813C Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists
07/29/2008CA2432222C Pyrazole compounds useful as protein kinase inhibitors
07/29/2008CA2432132C Pyrazole compounds useful as protein kinase inhibitors
07/29/2008CA2409842C 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
07/29/2008CA2405486C Method for synthesis of perindopril and its pharmaceutically acceptable salts
07/29/2008CA2401952C Pyranoindoles for treating glaucoma
07/29/2008CA2401033C 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
07/29/2008CA2387762C Process of making substituted pyrazoles
07/29/2008CA2383600C Method for determining viability of a myocardial segment
07/29/2008CA2382322C Aminocarbonyl-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions
07/29/2008CA2381729C Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
07/29/2008CA2377614C Anesthetic composition for intravenous injection comprising propofol
07/29/2008CA2376930C A method for the treatment or prevention of coronary graft vasospasm
07/29/2008CA2376303C Stabilized vitamin c formulations
07/29/2008CA2375601C Carbapenem compound crystals and injection preparations
07/29/2008CA2375383C Modulators of methylation for control of bacterial virulence
07/29/2008CA2374442C Silicone gel containing salicylic acid
07/29/2008CA2371857C Gardos channel antagonists
07/29/2008CA2368413C Derivatives of pyrimido[6,1-a]isoquinolin-4-one
07/29/2008CA2367214C Method for a programmed controlled ovarian stimulation protocol
07/29/2008CA2362343C Method and composition for treating acne
07/29/2008CA2362217C Process for preparing phenylpyrazole pesticidal intermediates
07/29/2008CA2359592C Pharmaceutical compositions for alleviating discomfort
07/29/2008CA2352149C Solid lipidic nanospheres suitable to a fast internalization into cells
07/29/2008CA2348742C Carbocyclic potassium channel inhibitors
07/29/2008CA2344893C Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
07/29/2008CA2337755C Inhibitors of p38
07/29/2008CA2336799C Improved stable topical ascorbic acid compositions
07/29/2008CA2333656C A novel vla-4 inhibitor: omepupa-v
07/29/2008CA2333008C New heterocyclically substituted amides, their production and their use
07/29/2008CA2328950C Piperidinopyrimidine derivatives for topical application
07/29/2008CA2324077C Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
07/29/2008CA2323315C Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
07/29/2008CA2307002C Antitumour uridine analogues
07/29/2008CA2295628C Stable formulations comprising a nucleotide and a freeze drying additive
07/29/2008CA2291685C Pharmaceutical product for the detection of helicobacter pylori-induced gastrointestinal disorder
07/29/2008CA2286822C Kodaistatins a, b, c and d, a process for their production and their use
07/29/2008CA2285909C Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same
07/29/2008CA2281817C Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
07/29/2008CA2275371C Phenylethylamine derivatives
07/29/2008CA2272732C Hemorrhoidal treatment composition